Changes in the Polish Market

This free white paper from Datamonitor Healthcare explores changes in the market access environment in Poland. An increasingly important European market, the Polish pharmaceutical market has recently undergone many changes. The Reimbursement Act, introduced in 2012, has had a negative impact on the reimbursed market segment in terms of changes in the reference pricing system and price renegotiation. However, the pricing and reimbursement process is now more transparent and predictable, and the introduction of risk-sharing schemes opens up opportunities for market access to high-cost therapies.

Highlights in this white paper include:

A discussion of the key measures of the Reimbursement Act of 2012 and their impact on the pharmaceutical market.
An analysis of the changes in the rate of addition of new medicines to reimbursement lists.
Insight into how risk-sharing schemes are used in Poland.

Changes in the Polish Market Whitepaper

Total pharmaceuticalsalesinPoland reached €5.0bn($6.6bn)in 2012,with key drivers of the market being the country's growing economy,increasing life expectancy, and an increase in per capita physician visits, offering substantial market potential for pharmaceutical products

Download whitepaper

Next steps

Request a Demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Speak to Sales

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Client Services

US Toll-Free : +1 888 670 8900
US Toll : +1 212-600-3520
UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now